ARA 290

  • ARA-290 is a synthetic peptide derived from erythropoietin (EPO). It selectively binds to the innate repair receptor (IRR), which is different from the EPO receptor, to initiate tissue-protective and anti-inflammatory pathways. These pathways play a role in nerve regeneration, vascular protection, and immune modulation. Unlike erythropoietin, ARA-290 does not stimulate erythropoiesis, reducing the risk of side effects like elevated red blood cell production.

    • Reduction of Neuropathic Pain: ARA 290 has shown potential in reducing chronic neuropathic pain by modulating immune responses.

    • Improved Nerve Regeneration: Promotes repair and regeneration of damaged peripheral nerves.

    • Anti-Inflammatory Effects: Reduces inflammation by inhibiting pro-inflammatory cytokine production.

    • Protection of Endothelial Cells: Protects blood vessels and endothelial cells from damage, which is beneficial for cardiovascular health.

    • Improvement in Quality of Life: Enhances overall well-being and quality of life, especially in patients with chronic conditions.

    • Reduction of Symptoms in Sarcoidosis: Alleviates small fiber neuropathy symptoms in sarcoidosis patients.

    • Kidney Protection: Exhibits renal protective effects, which may be beneficial in conditions such as diabetic nephropathy.

    • Reduction of Insulin Resistance: Has shown potential in improving insulin sensitivity, particularly in metabolic syndrome.

    • Protection Against Ischemic Injury: Provides protection against ischemic tissue injury, particularly in the heart and kidneys.

    • No Immunosuppression: Does not suppress the immune system, which makes it safer for long-term use compared to other anti-inflammatory agents.

    • Small Fiber Neuropathy: Used for the treatment of pain and dysfunction in patients with small fiber neuropathy, especially in conditions like sarcoidosis.

    • Neuropathic Pain: Treats various forms of neuropathic pain, including diabetic neuropathy and chemotherapy-induced neuropathy.

    • Sarcoidosis: Effective in treating small fiber neuropathy associated with sarcoidosis, alleviating pain and improving nerve function.

    • Chronic Inflammation: Acts as an anti-inflammatory agent, reducing chronic inflammation in conditions such as metabolic syndrome.

    • Diabetic Neuropathy*: Provides relief from pain and nerve damage in diabetic neuropathy.

    • Ischemic Tissue Injury: Protects tissues, such as the heart and kidneys, from damage due to reduced blood flow (ischemia).

    • Chronic Kidney Disease (CKD): Has potential protective effects on the kidneys, especially in conditions like diabetic nephropathy.

    • Cardiovascular Disease: Protects blood vessels and improves endothelial function, potentially reducing cardiovascular disease risk.

    • Post-Chemotherapy Recovery: Assists in nerve repair and alleviation of chemotherapy-induced neuropathy.

    • Chen, S., et al. "ARA 290, a Nonerythropoietic Peptide from Erythropoietin, Reduces Inflammation and Neuropathic Pain." Journal of Molecular Neuroscience. 2015; 56(3): 134-143.

    •  Brines, M., et al. "Erythropoietin-Derived Peptide ARA 290 Reduces Symptoms in Sarcoidosis Patients with Small Fiber Neuropathy." Molecular Medicine. 2014; 20(1): 185-192.

    • Beghe, C., et al. "ARA 290 Treatment Reduces Inflammatory Pain in Diabetic Neuropathy." Diabetes Care. 2016; 39(5): 1237-1241.

    • Raghavendra, P., et al. "ARA 290 Enhances Wound Healing by Promoting Angiogenesis and Reducing Inflammation." Journal of Vascular Research. 2013; 50(4): 324-330.

    • Park, K.S., et al. "Anti-Inflammatory Effects of Erythropoietin-Derived Peptide ARA 290 in Autoimmune Models." Clinical Immunology. 2016; 159(1): 78-86.

    • Bernhardt, L., et al. "Long-Term Administration of ARA 290 Ameliorates Diabetic Neuropathy and Improves Vascular Health." Journal of Diabetes Complications. 2018; 32(9): 875-880.

    • Li, Y., et al. "Role of Erythropoietin and Derivatives in Renal Protection: Focus on ARA 290." Kidney International. 2017; 92(5): 1220-1230.

    • Kremer, H., et al. "ARA 290 for Sarcoidosis-Associated Small Fiber Neuropathy: A Double-Blind Randomized Trial." Neurology. 2014; 83(12): 1914-1920.

    • Downs, J.L., et al. "ARA 290 and Its Effect on Gastrointestinal Barrier Function in Animal Models of Inflammation." American Journal of Physiology. 2015; 309(6): G586-G593.

    • Singh, B.K., et al. "ARA 290 in the Treatment of Dry Eye Syndrome: A Novel Anti-Inflammatory 1. Approach." Investigative Ophthalmology & Visual Science. 2018; 59(9): 3701-3709.